© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Cholangiocarcinoma Foundation launches New Career and Scientific Mentoring Programs by matching mentees and mentors within the ICRN and ENS-CCA networks.
SALT LAKE CITY, UT – Cholangiocarcinoma patients need scientists and researchers to help generate funding for research and treatment of early-stage cholangiocarcinoma, a rare but lethal bile duct cancer. The Foundation’s International Cholangiocarcinoma Research Network (ICRN) and the European Cholangiocarcinoma Network (ENS-CCA) created two new mentoring programs, called the Career Mentoring Program and Scientific Mentoring Program, to support and advise junior researchers in their career choices and scientific growth by matching mentees and mentors within the ICRN and ENS-CCA networks.
While mentorship is a well-developed practice in most high-volume cancer Institutions, tremendous clinical workloads lack access. Research resources and collaboration opportunities in community hospitals and low- and middle-income countries underscore the need to develop these mentorship programs. Our joint mentorship programs offer junior researchers the opportunity to get support from international, external and independent highly experienced physician-scientist mentors who share the same interest in cholangiocarcinoma.
These new programs help mentor young researchers:
Moreover, the Scientific Mentoring Program is designed to give junior researchers the opportunity to work closely with experts in various research areas, including cancer research, cell biology, genomics, artificial intelligence and other high-yield research areas in the cholangiocarcinoma research world. Thus, these programs support the Cholangiocarcinoma Foundation’s expansion of its stakeholder community and support to the new generation.
Applicants for the Career or Scientific Mentoring Programs must be:
About cholangiocarcinoma: Cholangiocarcinoma, pronounced (koh-LAN-jee-oh-KAR-sih-NOH-muh), is a highly lethal and rare bile duct cancer of the liver with a poor prognosis. With approximately 10,000 cases a year
diagnosed in the United States, cholangiocarcinoma is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.
About the Cholangiocarcinoma Foundation (CCF):Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization. Its mission is to find a cure and improve the quality of life for those affected by bile duct cancer. CCF supports basic & translational research and raises awareness in the cholangiocarcinoma community through advocacy, education, collaboration, and research. For more information, please visit our website at cholangiocarcinoma.org.